Research
Hormonal
GIP is the major physiological mediator of the incretin effect in healthy humans, contributing more to insulin secretion than GLP-1.
In healthy individuals, GIP is the primary driver of the 'incretin effect' (the boost in insulin after eating). This physiological fact underpins the rationale for using dual GIP/GLP-1 drugs in diabetes.
StrongSupportsHIGH confidence
Using this novel methodology, Gasbjerg et al.16 have confirmed the assumption that the contribution of GIP to mediating the incretin effect after oral glucose in healthy human subjects is far greater than that of GLP-1... Thus, GIP has been established as the major physiological incretin hormone.
Why this rating
Based on specific blockade studies (Gasbjerg et al.) cited in the review.
Source
The evolving story of incretins ( <scp>GIP</scp> and <scp>GLP</scp> ‐1) in metabolic and cardiovascular disease: A pathophysiological update
Michael A. Nauck et al. · Diabetes Obesity and Metabolism · 2021
DOI 10.1111/dom.14496
narrative_reviewCited 356×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Dual GIP/GLP-1 receptor agonism (e.g., tirzepatide) yields superior glycemic control and body weight reduction compared to selective GLP-1 receptor agonists.Good
- GIP promotes triglyceride storage in white adipose tissue and may contribute to ectopic fat accumulation (fatty liver) in mice, acting as an obesogenic hormone in this context.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →